In 2010, Is There Any Difference Between the Biopharmaceutical and Pharmaceutical Industry?

Latest report by Kalorama Information examines the current state of the biopharmaceutical and pharmaceutical industry, and what the market will look like in five years.
By: Kalorama Information
 
June 21, 2010 - PRLog -- The line between pharmaceutical companies and biopharmaceutical companies is blurred to the point of no longer being a distinct.  And perhaps we should stop using the terms soon.  This is one of the findings of the healthcare market research publisher Kalorama Information in its new World Pharmaceutical and Biopharmaceutical Market 2010-2015 (Pipeline Analysis of the Top 50 Companies)  http://www.kaloramainformation.com/Biopharmaceutical-Pipeline-Companies-2691449/.  

Among the top companies in biopharmaceuticals are, not surprisingly, the same names that have dominated pharmaceuticals for years – Pfizer, Merck and Novartis.  These companies have been unable to ignore the benefits of investing in biotechnology and have focused on a pipeline in this direction through strategic acquisitions and partnerships with biotech companies and/or through their own in-house research efforts.  Specialist companies such as Amgen and Genzyme, now competing with a growing number of companies.  The result of all interest in biological solutions to major diseases?  In creased activity in the research and development departments of major pharmaceutical companies in recent years, activity that we believe will have near-term market impact.    

“If you ask a traditional pharmco these days what they are, they are going to say a pharmaceutical and biopharmaceutical company,” said Mellisa Elder, analyst for Kalorama Information.  “The late-stage pipeline of Merck, Pfizer and Novartis features a good number of mabs and other biopharmaceutical candidates.”

Fifty companies produce 95% of the revenue in the pharmaceutical market.   Collectively, these companies have 550 programs in late stage development.    We include where one candidate is submitted for multiple indications.   Drugs in the oncology segment are expected to make a significant impact to current markets, increasing competition and providing advanced alternatives to current therapies.  Many of these are monoclonal antibodies or other biologic therapies.  Cancer drugs in development could possibly make up nearly a third of the market impact of all of these new treatments  This is followed by development projects in the areas of cardiovascular and blood; neurotherapeutics; respiratory and inflammation; infectious diseases; gastrointestinal drugs; and other drugs—areas such as diabetes; sexual dysfunction; dermatology not otherwise included in other segments; fertility drugs; hormones; osteoporosis treatments; renal disease; ocular treatments not otherwise included in other segments and other specialty segments.

The global pharmaceutical market is now worth approximately $600 billion (at the manufacturer’s level) and the United States accounts for roughly 40-50% of the world market. Even during economic recessions the industry moves forward, with an expected increase of 5%, at the global level in 2010. The largest therapeutic areas in medicine are cardiovascular, neurotherapeutics and oncology.  Cardiovascular is the largest in terms of revenues .  Oncology treatments have emerged more recently as the third largest segment in drug treatment.  This is largely due to the growing number of adjunctive therapies and high-cost of effective biotherapy including monoclonal antibodies.   Primary treatments include Rituxan, Avastin, Herceptin, and Gleevec..  

The World Pharmaceutical and Biopharmaceutical Market 2010-2015 (Pipeline Analysis of the Top 50 Companies) can be obtained at  http://www.kaloramainformation.com/Biopharmaceutical-Pipe...  

Please direct all media inquiries to:
Andrea Hiller
press@kaloramainformation.com
http://www.kaloramainformation.com/

# # #

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter: www.twitter.com/KaloramaInfo.
End
Source:Kalorama Information
Email:***@kaloramainformation.com Email Verified
Tags:Pharmaceutical, Biopharmaceutical, Medical, Health, Medicine, Healthcare, Biotechnology, Pharmco, Drugs, Oncology
Industry:Health, Medical, Science
Location:New York City - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share